ONYX PHARMACEUTICALS INC 4
4 · ONYX PHARMACEUTICALS INC · Filed Jul 2, 2013
Insider Transaction Report
Form 4
Lasowski Juergen
SVP, Corporate Development
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−25,375→ 2,625 totalExercise: $28.55Exp: 2019-03-31→ Common Stock (25,375 underlying) - Exercise/Conversion
Common Stock
2013-07-01$28.55/sh+25,375$724,456→ 57,458 total - Sale
Common Stock
2013-07-01$132.63/sh−25,375$3,365,486→ 32,083 total
Footnotes (2)
- [F1]Shares sold pursuant to 10b5-1 plan.
- [F2]Fully vested.